1-11 of 11
aldesleukin
Close
Sort by
Journal Articles

First-in-human phase 1 trial of induced regulatory T cells for graft-versus-host disease prophylaxis in HLA-matched siblings

Clinical Trials & Observations
Margaret L. MacMillan, Keli L. Hippen, David H. McKenna, Diane Kadidlo, Darin Sumstad, Todd E. DeFor, Claudio G. Brunstein, Shernan G. Holtan, Jeffrey S. Miller, Erica D. Warlick, Daniel J. Weisdorf, John E. Wagner, Bruce R. Blazar
Journal: Blood Advances
Blood Adv (2021) 5 (5): 1425–1436.
https://doi.org/10.1182/bloodadvances.2020003219
Published: 2021
Includes: Supplemental data
Journal Articles

IL-2 enhances ex vivo–expanded regulatory T-cell persistence after adoptive transfer

Scott N. Furlan, Karnail Singh, Christina Lopez, Victor Tkachev, Daniel Joel Hunt, James Hibbard, Kayla M. Betz, Bruce R. Blazar, Cole Trapnell, Leslie S. Kean
Journal: Blood Advances
Blood Adv (2020) 4 (8): 1594–1605.
https://doi.org/10.1182/bloodadvances.2019001248
Published: 2020
Includes: Supplemental data
Journal Articles

Diversity of peripheral blood human NK cells identified by single-cell RNA sequencing

Samantha L. Smith, Philippa R. Kennedy, Kevin B. Stacey, Jonathan D. Worboys, Annie Yarwood, Seungmae Seo, Everardo Hegewisch Solloa, Brandon Mistretta, Sujash S. Chatterjee, Preethi Gunaratne, Kimaada Allette, Ying-Chih Wang, Melissa Laird Smith, Robert Sebra, Emily M. Mace, Amir Horowitz, Wendy Thomson, Paul Martin, Steve Eyre, Daniel M. Davis
Journal: Blood Advances
Blood Adv (2020) 4 (7): 1388–1406.
https://doi.org/10.1182/bloodadvances.2019000699
Published: 2020
Includes: Supplemental data
Journal Articles

Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children

Clinical Trials & Observations
Jennifer S. Whangbo, Haesook T. Kim, Nikola Mirkovic, Lauren Leonard, Samuel Poryanda, Sophie Silverstein, Soomin Kim, Carol G. Reynolds, Sharmila C. Rai, Kelly Verrill, Michelle A. Lee, Steven Margossian, Christine Duncan, Leslie Lehmann, Jennifer Huang, Sarah Nikiforow, Edwin P. Alyea, III, Philippe Armand, Corey S. Cutler, Vincent T. Ho, Bruce R. Blazar, Joseph H. Antin, Robert J. Soiffer, Jerome Ritz, John Koreth
Journal: Blood Advances
Blood Adv (2019) 3 (17): 2550–2561.
https://doi.org/10.1182/bloodadvances.2019000631
Published: 2019
Includes: Supplemental data
Journal Articles

Assessment of TCR signal strength of antigen-specific memory CD8 + T cells in human blood

Hanchih Wu, Ashley Witzl, Hideki Ueno
Journal: Blood Advances
Blood Adv (2019) 3 (14): 2153–2163.
https://doi.org/10.1182/bloodadvances.2019000292
Published: 2019
Includes: Supplemental data
Journal Articles

First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia

Clinical Trials & Observations
Sarah Cooley, Fiona He, Veronika Bachanova, Gregory M. Vercellotti, Todd E. DeFor, Julie M. Curtsinger, Paul Robertson, Bartosz Grzywacz, Kevin C. Conlon, Thomas A. Waldmann, David H. McKenna, Bruce R. Blazar, Daniel J. Weisdorf, Jeffrey S. Miller
Journal: Blood Advances
Blood Adv (2019) 3 (13): 1970–1980.
https://doi.org/10.1182/bloodadvances.2018028332
Published: 2019
Includes: Supplemental data
Journal Articles

Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease

Clinical Trials & Observations
Roger Belizaire, Haesook T. Kim, Samuel J. Poryanda, Nikola V. Mirkovic, Evelyn Hipolito, William J. Savage, Carol G. Reynolds, Marie J. Fields, Jennifer Whangbo, Tomohiro Kubo, Sarah Nikiforow, Edwin P. Alyea, Philippe Armand, Corey S. Cutler, Vincent T. Ho, Bruce R. Blazar, Joseph H. Antin, Jerome Ritz, Robert J. Soiffer, John Koreth
Journal: Blood Advances
Blood Adv (2019) 3 (7): 969–979.
https://doi.org/10.1182/bloodadvances.2018029124
Published: 2019
Includes: Supplemental data
Journal Articles

Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease

Clinical Trials & Observations
Jennifer S. Whangbo, Haesook T. Kim, Sarah Nikiforow, John Koreth, Ana C. Alho, Bryn Falahee, Soomin Kim, Katharine Dusenbury, Marie J. Fields, Carol G. Reynolds, Edwin P. Alyea, III, Philippe Armand, Corey S. Cutler, Vincent T. Ho, Joseph H. Antin, Robert J. Soiffer, Jerome Ritz
Journal: Blood Advances
Blood Adv (2019) 3 (7): 984–994.
https://doi.org/10.1182/bloodadvances.2018027474
Published: 2019
Includes: Supplemental data
Journal Articles

Interleukin-2–inducible T-cell kinase inhibitors modify functional polarization of human peripheral T-cell lymphoma cells

Sami Mamand, Matthew Carr, Rebecca L. Allchin, Matthew J. Ahearne, Simon D. Wagner
Journal: Blood Advances
Blood Adv (2019) 3 (5): 705–710.
https://doi.org/10.1182/bloodadvances.2018027821
Published: 2019
Includes: Supplemental data
Journal Articles

Long-term follow-up of a phase 3 clinical trial of inolimomab for the treatment of primary steroid refractory aGVHD

Clinical Trials & Observations
Gérard Socié, Noel Milpied, Ibrahim Yakoub-Agha, Jacques-Olivier Bay, Sabine Fürst, Karin Bilger, Felipe Suarez, Mauricette Michallet, Philippe Lewalle, David Liens, Catherine Mathis, Eric Guemas, Jean-Paul Vernant
Journal: Blood Advances
Blood Adv (2019) 3 (2): 184–186.
https://doi.org/10.1182/bloodadvances.2018028282
Published: 2019
Journal Articles

IL-33, IL-25, and TSLP induce a distinct phenotypic and activation profile in human type 2 innate lymphoid cells

Ana Camelo, Guglielmo Rosignoli, Yoichiro Ohne, Ross A. Stewart, Catherine Overed-Sayer, Matthew A. Sleeman, Richard D. May
Journal: Blood Advances
Blood Adv (2017) 1 (10): 577–589.
https://doi.org/10.1182/bloodadvances.2016002352
Published: 2017
Includes: Supplemental data